First and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome reaches patients through LogiCare3PL’s specialty pharmaceutical logistics platform
LogiCare3PL is proud to support the commercial launch of VYKAT XR, Soleno Therapeutics’ newly FDA-approved therapy and the first and only treatment indicated for hyperphagia in patients with Prader-Willi syndrome (PWS). This milestone marks a significant advancement for the PWS community.
“Managing the complex logistics behind the launch of this first-in-class therapy is a responsibility we take seriously,” said Christian Carrier, Director, Client Services at LogiCare3PL. “VYKAT™ XR is more than a product—it represents real hope for patients and families, and we’re honored to help make it accessible.”
Health Technology Insights: MAP Medical Launches as Innovative Medical Supply Concierge
For the first time, individuals with PWS—who live with chronic, insatiable hunger caused by hyperphagia—have access to a therapy designed to directly address this debilitating symptom.
Soleno Therapeutics team members were on-site to commemorate the launch, connecting with operations staff and emphasizing the personal impact of every shipment—reinforcing the shared mission behind patient-focused logistics.
“This is a breakthrough moment for families affected by Prader-Willi syndrome,” said Kevin Kissling, Vice President & General Manager at LogiCare3PL. “We’re proud to partner with Soleno Therapeutics to help bring VYKAT™ XR to patients and support timely access to this long-awaited treatment.”
LogiCare3PL remains committed to delivering tailored logistics solutions that help its partners expand access to transformative therapies—swiftly, securely, and with care.
Health Technology Insights: Veracyte expands Decipher Prostate Test availability for metastatic prostate cancer patients
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
